- Home
- FFIN vs MDGL Comparison
FFIN vs MDGL Comparison
Compare FFIN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIN
- MDGL
- Stock Information
- Founded
- FFIN 1890
- MDGL 2011
- Country
- FFIN United States
- MDGL United States
- Employees
- FFIN N/A
- MDGL N/A
- Industry
- FFIN Major Banks
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- FFIN Finance
- MDGL Health Care
- Exchange
- FFIN Nasdaq
- MDGL Nasdaq
- Market Cap
- FFIN 5.3B
- MDGL 6.1B
- IPO Year
- FFIN N/A
- MDGL N/A
- Fundamental
- Price
- FFIN $36.73
- MDGL $432.89
- Analyst Decision
- FFIN Hold
- MDGL Strong Buy
- Analyst Count
- FFIN 4
- MDGL 10
- Target Price
- FFIN $39.50
- MDGL $463.78
- AVG Volume (30 Days)
- FFIN 536.9K
- MDGL 402.0K
- Earning Date
- FFIN 10-16-2025
- MDGL 10-30-2025
- Dividend Yield
- FFIN 2.07%
- MDGL N/A
- EPS Growth
- FFIN 21.27
- MDGL N/A
- EPS
- FFIN 1.71
- MDGL N/A
- Revenue
- FFIN $578,401,000.00
- MDGL $515,547,000.00
- Revenue This Year
- FFIN $20.88
- MDGL $394.12
- Revenue Next Year
- FFIN $5.94
- MDGL $57.74
- P/E Ratio
- FFIN $21.46
- MDGL N/A
- Revenue Growth
- FFIN 16.40
- MDGL 3421.98
- 52 Week Low
- FFIN $30.58
- MDGL $200.63
- 52 Week High
- FFIN $44.66
- MDGL $443.00
- Technical
- Relative Strength Index (RSI)
- FFIN 52.72
- MDGL 75.83
- Support Level
- FFIN $36.23
- MDGL $422.02
- Resistance Level
- FFIN $38.12
- MDGL $443.00
- Average True Range (ATR)
- FFIN 0.89
- MDGL 16.41
- MACD
- FFIN 0.05
- MDGL 0.56
- Stochastic Oscillator
- FFIN 53.97
- MDGL 88.97
About FFIN First Financial Bankshares Inc.
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.